Margreet Franken

Assistant professor

Erasmus Universiteit Rotterdam Erasmus School of Health Policy and Management

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Margreet Franken is an Assistant Professor at the Erasmus School of Health Policy & Management, Erasmus Universiteit Rotterdam, Netherlands. Her research focuses on healthcare costs, survival trends, and treatment effectiveness in oncology, particularly concerning melanoma and multiple myeloma. Recent publications include studies on reimbursement processes, cost-effectiveness of novel treatments, and healthcare costs associated with advanced melanoma therapies.

Articles (9)

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Alexander Christopher Jonathan van Akkooi

Associate Professor

Melanoma Institute Australia

AUSTRALIA

View details

Brenda Leeneman

Assistant professor

Erasmus Universiteit Rotterdam Erasmus School of Health Policy and Management

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Margreet Franken

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab

Collaborators (2)

Alexander Christopher Jonathan van Akkooi

Brenda Leeneman

Make your next move.